Clinical trial

Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy

NCT04467801

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Ipatasertib Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2021-09-14

PhasePHASE2

Conditions

NSCLC Stage IVunresolved

NSCLC Stage IIIBunresolved

Interventions

IpatasertibDRUG

Sponsors & collaborators

Jun Zhang, MD, PhDlead sponsor

University of Iowacollaborator

University of Kentuckycollaborator

Mapped research locations

Kansas CityMissouri, United States1 Kansas CityKansas, United States1 Overland ParkKansas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04467801 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.